吸入糖皮质激素联合长效β2-受体激动剂对慢性阻塞性肺疾病的疗效

Efficacy of inhaled glucocorticoid and long-acting beta-2-receptor agonists in patients with chronic obstructive pulmonary disease

目的分析应用长效β2-受体激动剂与糖皮质激素联合疗法在慢性阻塞性肺疾病患者治疗中的作用。方法随机选择2015年5月-2016年5月于我院接受治疗的中重度慢性阻塞性肺疾病患者100例,按照随机数字表法分为单一药物组与联合药物组,每组50例。其中单一药物组患者采用吸入药物福莫特罗的疗法,而联合药物组患者应用吸入药物福莫特罗联合布地奈德的疗法。分析两组患者在治疗前、治疗后1个月与3个月时的肺功能状况。结果两组患者在治疗前的肺功能指标没有统计学差异(P>0.05);两组患者在治疗后1个月与3个月时的肺功能状况比治疗前显著改善(P<0.05),联合药物组患者在治疗后1个月与3个月时的肺功能状况比单一药物组显著改善,差异有统计学意义(P<0.05)。结论应用长效β2-受体激动剂与糖皮质激素联合疗法在慢性阻塞性肺疾病患者治疗中的作用优异,可有效增强机体的肺功能状况。

Objective To analyze the efficacy of inhaled glucocorticoid and long-acting beta-2-receptoragonists in patients with chronic obstructive pulmonary disease.Methods A total of100patients with moderate tosevere chronic obstructive pulmonary disease treated in our hospital from May2015to May2016were randomlyselected.The patients were randomly divided into single group and combined group,with50cases in each group.The patients in single drug group were treated with formoterol inhalation drug therapy,and patients in combineddrug group were treated with formoterol and budesonide inhalation drug therapy.The pulmonary function beforetreatment and one month and three months after treatment of patients in two groups were analyzed.Results Therewas no significant difference in pulmonary function between the two groups before treatment(P>0.05).The pulmonaryfunction of patients in two groups after treatment for1month and3months was significantly improved thanthat of before treatment(P<0.05).The pulmonary function of patients in combined drug group after treatment for1month and3months was significantly improved than those of single drug group(P<0.05).Conclusion Applicationof long-acting beta-2-receptor agonist and glucocorticoid therapy in the treatment of patients with chronic obstructivepulmonary disease has a good effect,can effectively enhance the body's lung function.